Breaking New Ground with DecisionDx-SCC Test
Recent studies have revealed groundbreaking insights into how the DecisionDx-SCC test can significantly improve treatment decisions for patients at high risk of cutaneous squamous cell carcinoma (SCC). This innovative gene expression profile test, produced by Castle Biosciences, focuses on individual tumor biology, thus offering precise predictions related to the risk of metastasis and local recurrence.
Significant Outcomes from Recent Studies
From recent validation studies, it is evident that DecisionDx-SCC significantly outperforms existing staging systems. This is particularly important for patients classified as high-risk according to National Comprehensive Cancer Network (NCCN) guidelines who undergo Mohs resection. The studies indicate that the test now has three validated uses: predicting metastasis, anticipating response to adjuvant radiation therapy (ART), and estimating the risk of local recurrence. These advancements provide a more comprehensive quintessence for developing tailored post-surgical treatment plans.
Clinician Surveys Indicate Crucial Decision-Making Support
Moreover, a survey conducted among clinicians revealed that the results of the DecisionDx-SCC test align perfectly with their treatment decision-making criteria regarding ART and necessary surveillance imaging. This helps doctors make informed choices based on the risk profiles of their patients.
The Transformative Impact of Individualized Risk Predictions
"The new data indicates that DecisionDx-SCC provides individualized risk assessments that allow physicians to adapt their treatment strategies more effectively," said Dr. Désirée Ratner, a Mohs micrographic surgeon and clinical professor at NYU Grossman School of Medicine. By specifically identifying risks related to local recurrence and metastasis, physicians' practices regarding SCC treatment can drastically transform, ultimately enhancing patient outcomes.
The Clinical Need for Improved Risk Stratification
As usual, most patients with NCCN high-risk SCC successfully undergo treatment via Mohs surgery. However, some of these patients will unfortunately experience local recurrences or metastasis. Current staging protocols — such as those from the American Joint Committee on Cancer (AJCC) Version 8 and Brigham and Women’s Hospital (BWH) T-staging systems — fall short in discerning which patients face the highest risks of poor outcomes. This gap underscores an urgent requirement for advanced risk stratification tools that can provide clinicians with better guidance on treatment strategies.
Outcomes Highlighted Within the Studies
The latest findings from 414 high-risk NCCN SCC patients highlighted that DecisionDx-SCC could significantly stratify risks for both local recurrence and metastasis effectively. The three-year survival rates showcased a clear distinction across risk classes — local recurrence-free survival rates showed a stark drop among those designated as Class 1 (low risk), Class 2A (higher risk), and Class 2B (highest risk). Conversely, current staging systems revealed inadequate differentiation of these risks.
DecisionDx-SCC: A Pathway Towards Improved Treatment Strategies
The DecisionDx-SCC test results not only offer a class stratification (Class 1 to Class 2B) that informs future management plans, but it provides actionable insights that clinicians can depend on. For instance, clinicians reported using Class 2B results as among the most critical factors when evaluating management decisions for ART, anticipating it would significantly influence their care pathways.
About Castle Biosciences and DecisionDx-SCC
Castle Biosciences, Inc. (NASDAQ: CSTL), is pioneering advancements in diagnostic testing aimed at improving patient care, including tests for skin cancers and other high-need conditions such as Barrett's esophagus and melanoma. The goal of the company is to establish disease management pathways that reflect patient needs first. Learn more about the transformative impact of their advancements in diagnostics and patient care.
Frequently Asked Questions
What is DecisionDx-SCC?
DecisionDx-SCC is a 40-gene expression profile test specifically designed to evaluate the risk of metastasis for patients with high-risk cutaneous squamous cell carcinoma.
How does DecisionDx-SCC improve treatment choices?
The test provides individualized risk predictions that help clinicians make informed decisions regarding treatment strategies tailored to individual patient needs.
What were the major findings of the studies?
The studies demonstrated that DecisionDx-SCC significantly predicts risks of local recurrence and metastasis, surpassing traditional staging system adequacy in assessing patient risks.
Who benefits from this test?
Patients classified as high-risk by NCCN guidelines who undergo Mohs surgery can gain crucial insights from the DecisionDx-SCC test to better inform their post-surgical treatment pathways.
Where can I learn more about Castle Biosciences?
More information about Castle Biosciences and their innovative solutions can be found on their website and by connecting with them on various social media platforms.
